BACKGROUND: Syphilis management requires serological monitoring after therapy. We compared factors associated with serological response after treatment of early (ie, primary, secondary, or early latent) syphilis. METHODS: We performed secondary analyses of data from a prospective, randomized syphilis trial conducted in the United States and Madagascar. Human immunodeficiency virus (HIV)-negative participants aged ≥ 18 years with early syphilis were enrolled from 2000-2009. Serological testing was performed at baseline and at 3 and 6 months after treatment. At 6 months, serological cure was defined as a negative rapid plasma reagin (RPR) test or a ≥4-fold decreased titer, and serofast status was defined as a ≤ 2-fold decreased titer or persistent titers that did not meet criteria for treatment failure. RESULTS: Data were available from 465 participants, of whom 369 (79%) achieved serological cure and 96 (21%) were serofast. In bivariate analysis, serological cure was associated with younger age, fewer sex partners, higher baseline RPR titers, and earlier syphilis stage (P ≤ .008). There was a less significant association with Jarisch-Herxheimer reaction after treatment (P = .08). Multivariate analysis revealed interactions between log-transformed baseline titer with syphilis stage, in which the likelihood of cure was associated with increased titers among participants with primary syphilis (adjusted odds ratio [AOR] for 1 unit change in log(2) titer, 1.83; 95% confidence interval [CI], 1.25-2.70), secondary syphilis (AOR, 3.15; 95% CI, 2.14-4.65), and early latent syphilis (AOR, 1.86; 95% CI, 1.44-2.40). CONCLUSIONS:Serological cure at 6 months after early syphilis treatment is associated with age, number of sex partners, Jarisch-Herxheimer reaction, and an interaction between syphilis stage and baseline RPR titer.
RCT Entities:
BACKGROUND: Syphilis management requires serological monitoring after therapy. We compared factors associated with serological response after treatment of early (ie, primary, secondary, or early latent) syphilis. METHODS: We performed secondary analyses of data from a prospective, randomized syphilis trial conducted in the United States and Madagascar. Human immunodeficiency virus (HIV)-negative participants aged ≥ 18 years with early syphilis were enrolled from 2000-2009. Serological testing was performed at baseline and at 3 and 6 months after treatment. At 6 months, serological cure was defined as a negative rapid plasma reagin (RPR) test or a ≥4-fold decreased titer, and serofast status was defined as a ≤ 2-fold decreased titer or persistent titers that did not meet criteria for treatment failure. RESULTS: Data were available from 465 participants, of whom 369 (79%) achieved serological cure and 96 (21%) were serofast. In bivariate analysis, serological cure was associated with younger age, fewer sex partners, higher baseline RPR titers, and earlier syphilis stage (P ≤ .008). There was a less significant association with Jarisch-Herxheimer reaction after treatment (P = .08). Multivariate analysis revealed interactions between log-transformed baseline titer with syphilis stage, in which the likelihood of cure was associated with increased titers among participants with primary syphilis (adjusted odds ratio [AOR] for 1 unit change in log(2) titer, 1.83; 95% confidence interval [CI], 1.25-2.70), secondary syphilis (AOR, 3.15; 95% CI, 2.14-4.65), and early latent syphilis (AOR, 1.86; 95% CI, 1.44-2.40). CONCLUSIONS: Serological cure at 6 months after early syphilis treatment is associated with age, number of sex partners, Jarisch-Herxheimer reaction, and an interaction between syphilis stage and baseline RPR titer.
Authors: Gabriele Riedner; Mary Rusizoka; Jim Todd; Leonard Maboko; Michael Hoelscher; Donan Mmbando; Eleuter Samky; Eligius Lyamuya; David Mabey; Heiner Grosskurth; Richard Hayes Journal: N Engl J Med Date: 2005-09-22 Impact factor: 91.245
Authors: R T Rolfs; M R Joesoef; E F Hendershot; A M Rompalo; M H Augenbraun; M Chiu; G Bolan; S C Johnson; P French; E Steen; J D Radolf; S Larsen Journal: N Engl J Med Date: 1997-07-31 Impact factor: 91.245
Authors: Edward W Hook; Frieda Behets; Kathleen Van Damme; Noro Ravelomanana; Peter Leone; Arlene C Sena; David Martin; Carol Langley; Linda McNeil; Mark Wolff Journal: J Infect Dis Date: 2010-06-01 Impact factor: 5.226
Authors: Arlene C Seña; Mark Wolff; Frieda Behets; David H Martin; Peter Leone; Carol Langley; Linda McNeil; Edward W Hook Journal: Sex Transm Dis Date: 2017-01 Impact factor: 2.830
Authors: Arlene C Seña; Mark Wolff; Frieda Behets; Kathleen Van Damme; David H Martin; Peter Leone; Linda McNeil; Edward W Hook Journal: Clin Infect Dis Date: 2012-11-01 Impact factor: 9.079
Authors: Rosanna W Peeling; David Mabey; Mary L Kamb; Xiang-Sheng Chen; Justin D Radolf; Adele S Benzaken Journal: Nat Rev Dis Primers Date: 2017-10-12 Impact factor: 52.329